Global Cannabis Stock Index Falls, Nearly But Not Quite Breaking 11-Month Losing Streak

The Global Cannabis Stock Index fell for the 12th consecutive month, declining 1.1% to 28.31, reported Alan Brochstein, founder of New Cannabis Ventures and 420 Investor.

The index, which was down 27% in Q4 and then fell 12.9% in January, had 38 qualifying members during the month. The index has declined 13.8% in 2022, noted Brochstein.

After increasing 5.2% in 2020, it fell 26.0% in 2021 to 32.85 and has declined 69.4% from its 2021 closing high of 92.48 on February 10, 2021.

After posting an all-time closing low of 16.95 set on March 18, 2020, the index remains 67.0% higher but still down 84.3% from its early 2018 closing high at 180.02:

The strongest 4 names in February all gained at least 13%:

• IM Cannabis (CSE: IMCC) (NASDAQ: IMCC): +30.3%
• Flora Growth (NASDAQ: FLGC): +19.9%
• WM Technology (NASDAQ: MAPS): +15.4%
• Cresco Labs (CSE: CL) (OTC: CRLBF): +13.5%

IM Cannabis bounced back, said Brochstein, from a difficult January when it was among the weakest names. Flora Growth, which started as a $5 IPO in May 2021, is now up in 2022 but down 59% since its IPO. WM Technology rallied after its Q4 financial report, with revenue exceeding analysts' expectations. Cresco Labs has been the strongest Tier 1 MSO thus far in 2022, rallying nearly 5%.

The 4 weakest names in February all declined by more than 17%:

• Greenlane (NASDAQ: GNLN): -29.1%
• iPower (NASDAQ: IPW): -23.1%
• Power REIT (NYSE American: PW): -22.8%
• cbdMD (NYSE American: YCBD): -17.3%

Brochstein noted that the three weakest names are from the ancillary sector, which has been under pressure in 2022. Greenlane has declined 44.0% year-to-date, iPower has lost 37.0%, and Power REIT has dropped 30.0%. cbdMD fell sharply after reporting its Q1 financials and is down 20.4% in 2022.

Photo by Christine Roy on Unsplash